Literature DB >> 24504901

Roles for the TGFβ superfamily in the development and survival of midbrain dopaminergic neurons.

Shane V Hegarty1, Aideen M Sullivan, Gerard W O'Keeffe.   

Abstract

The adult midbrain contains 75% of all dopaminergic neurons in the CNS. Within the midbrain, these neurons are divided into three anatomically and functionally distinct clusters termed A8, A9 and A10. The A9 group plays a functionally non-redundant role in the control of voluntary movement, which is highlighted by the motor syndrome that results from their progressive degeneration in the neurodegenerative disorder, Parkinson's disease. Despite 50 years of investigation, treatment for Parkinson's disease remains symptomatic, but an intensive research effort has proposed delivering neurotrophic factors to the brain to protect the remaining dopaminergic neurons, or using these neurotrophic factors to differentiate dopaminergic neurons from stem cell sources for cell transplantation. Most neurotrophic factors studied in this context have been members of the transforming growth factor β (TGFβ) superfamily. In recent years, an intensive research effort has focused on understanding the function of these proteins in midbrain dopaminergic neuron development and their role in the molecular architecture that regulates the development of this brain region, with the goal of applying this knowledge to develop novel therapies for Parkinson's disease. In this review, the current evidence showing that TGFβ superfamily members play critical roles in the regulation of midbrain dopaminergic neuron induction, differentiation, target innervation and survival during embryonic and postnatal development is analysed, and the implications of these findings are discussed.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24504901     DOI: 10.1007/s12035-014-8639-3

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  189 in total

Review 1.  Neural patterning in the vertebrate embryo.

Authors:  C R Altmann; A H Brivanlou
Journal:  Int Rev Cytol       Date:  2001

Review 2.  The transforming growth factor-betas: structure, signaling, and roles in nervous system development and functions.

Authors:  M Böttner; K Krieglstein; K Unsicker
Journal:  J Neurochem       Date:  2000-12       Impact factor: 5.372

Review 3.  Signaling of transforming growth factor-beta family members through Smad proteins.

Authors:  S Itoh; F Itoh; M J Goumans; P Ten Dijke
Journal:  Eur J Biochem       Date:  2000-12

4.  Distinct activities of Msx1 and Msx3 in dorsal neural tube development.

Authors:  Ying Liu; Amy W Helms; Jane E Johnson
Journal:  Development       Date:  2004-03       Impact factor: 6.868

5.  Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial.

Authors:  William J Marks; Raymond T Bartus; Joao Siffert; Charles S Davis; Andres Lozano; Nicholas Boulis; Jerrold Vitek; Mark Stacy; Dennis Turner; Leonard Verhagen; Roy Bakay; Raymond Watts; Barton Guthrie; Joseph Jankovic; Richard Simpson; Michele Tagliati; Ron Alterman; Matthew Stern; Gordon Baltuch; Philip A Starr; Paul S Larson; Jill L Ostrem; John Nutt; Karl Kieburtz; Jeffrey H Kordower; C Warren Olanow
Journal:  Lancet Neurol       Date:  2010-10-20       Impact factor: 44.182

Review 6.  Morphogens and the control of cell proliferation and patterning in the spinal cord.

Authors:  Fausto Ulloa; James Briscoe
Journal:  Cell Cycle       Date:  2007-08-01       Impact factor: 4.534

7.  An early requirement for FGF signalling in the acquisition of neural cell fate in the chick embryo.

Authors:  S I Wilson; E Graziano; R Harland; T M Jessell; T Edlund
Journal:  Curr Biol       Date:  2000-04-20       Impact factor: 10.834

8.  Parallel induction of the formation of dopamine and its metabolites with induction of tyrosine hydroxylase expression in foetal rat and human cerebral cortical cells by brain-derived neurotrophic factor and glial-cell derived neurotrophic factor.

Authors:  S Theofilopoulos; J Goggi; S S Riaz; E Jauniaux; G M Stern; H F Bradford
Journal:  Brain Res Dev Brain Res       Date:  2001-04-30

9.  Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration.

Authors:  A M Sullivan; J Opacka-Juffry; J Pohl; S B Blunt
Journal:  Brain Res       Date:  1999-02-06       Impact factor: 3.252

Review 10.  Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways.

Authors:  Marie-Jose Goumans; Franck Lebrin; Gudrun Valdimarsdottir
Journal:  Trends Cardiovasc Med       Date:  2003-10       Impact factor: 6.677

View more
  13 in total

1.  Canonical BMP-Smad signalling promotes neurite growth in rat midbrain dopaminergic neurons.

Authors:  Shane V Hegarty; Louise M Collins; Aisling M Gavin; Sarah L Roche; Sean L Wyatt; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuromolecular Med       Date:  2014-03-29       Impact factor: 3.843

Review 2.  The role of TGF-β superfamily signaling in neurological disorders.

Authors:  Risa Kashima; Akiko Hata
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2018-01-01       Impact factor: 3.848

3.  Deficiency in Neuronal TGF-β Signaling Leads to Nigrostriatal Degeneration and Activation of TGF-β Signaling Protects against MPTP Neurotoxicity in Mice.

Authors:  Ina Tesseur; Andy Nguyen; Betty Chang; Lulin Li; Nathaniel S Woodling; Tony Wyss-Coray; Jian Luo
Journal:  J Neurosci       Date:  2017-03-31       Impact factor: 6.167

4.  TGFβ and Wnt Signaling Pathways Cooperatively Enhance Early Dopaminergic Differentiation of the Unrestricted Somatic Stem Cells.

Authors:  Azimeh Akhlaghpour; Azita Parvaneh Tafreshi; Eleni Roussa; Claude Bernard; Bahman Zeynali
Journal:  J Mol Neurosci       Date:  2020-02-10       Impact factor: 3.444

5.  Identification and Profiling of Environmental Chemicals That Inhibit the TGFβ/SMAD Signaling Pathway.

Authors:  Zhengxi Wei; Srilatha Sakamuru; Li Zhang; Jinghua Zhao; Ruili Huang; Nicole C Kleinstreuer; Yanling Chen; Yan Shu; Thomas B Knudsen; Menghang Xia
Journal:  Chem Res Toxicol       Date:  2019-11-11       Impact factor: 3.739

Review 6.  Neurotrophic factors: from neurodevelopmental regulators to novel therapies for Parkinson's disease.

Authors:  Shane V Hegarty; Gerard W O'Keeffe; Aideen M Sullivan
Journal:  Neural Regen Res       Date:  2014-10-01       Impact factor: 5.135

7.  Zeb2 is a negative regulator of midbrain dopaminergic axon growth and target innervation.

Authors:  Shane V Hegarty; Sean L Wyatt; Laura Howard; Elke Stappers; Danny Huylebroeck; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Sci Rep       Date:  2017-08-17       Impact factor: 4.379

8.  Inhibition of miR-181a promotes midbrain neuronal growth through a Smad1/5-dependent mechanism: implications for Parkinson's disease.

Authors:  Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Neuronal Signal       Date:  2018-01-26

Review 9.  Targeting bone morphogenetic protein signalling in midbrain dopaminergic neurons as a therapeutic approach in Parkinson's disease.

Authors:  Gerard W O'Keeffe; Shane V Hegarty; Aideen M Sullivan
Journal:  Neuronal Signal       Date:  2017-03-31

10.  Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients.

Authors:  Stylianos Ravanidis; Anastasia Bougea; Nikolaos Papagiannakis; Christos Koros; Athina Maria Simitsi; Ioanna Pachi; Marianthi Breza; Leonidas Stefanis; Epaminondas Doxakis
Journal:  Ann Clin Transl Neurol       Date:  2020-08-29       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.